GMP/FDA requirements to aseptic production

被引：0

作者：

Langer, U

Mangel, A

机构：

[1] Concept Heidelberg, D-69007 Heidelberg, Germany

[2] Univ Mainz Klinikum, Mainz, Germany

来源：

PHARMAZEUTISCHE INDUSTRIE | 2002年 / 64卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：375 / 383

页数：9

共 50 条

[1] The new FDA Aseptic Guidance/part 1: Hygiene requirements
Seyfarth, H
PHARMAZEUTISCHE INDUSTRIE, 2005, 67 (10): : 1194 - +
[2] Scope of regulation and GMP requirements in biotechnological production
Müller, D
PHARMAZEUTISCHE INDUSTRIE, 2005, 67 (11): : 1343 - 1358
[3] The appropriate implementation of GACP and GMP requirements for the production of herbal preparations
Brand, Norbert
Brueckner, Thomas
Gaedcke, Frauke
Steinhoff, Barbara
PHARMAZEUTISCHE INDUSTRIE, 2008, 70 (08): : 999 - 1005
[4] FDA overhauls GMP inspection
不详
CHEMICAL & ENGINEERING NEWS, 2003, 81 (08) : 9 - 10
[5] THE IMPACT OF THE FDA GMP REGULATION
BORGHESE, RN
JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1990, 9 (01): : 105 - 106
[6] FDA proposes GMP revisions
不详
BIOPHARM INTERNATIONAL, 2008, 21 (01) : 10 - 10
[7] GMP aspects in practice:: Requirements upon premises and facilities for the production of API
Brämert, M
PHARMAZEUTISCHE INDUSTRIE, 2005, 67 (07): : 817 - 818
[8] VALIDATION - FDA PRESSURE FOR GMP PROOF
不详
DRUG & COSMETIC INDUSTRY, 1980, 127 (06): : 44 - &
[9] FDA moves to streamline GMP inspections
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2007, 20 (06) : 22 - +
[10] Requirements for FDA Approval
Basu, Sankar
PROCEEDINGS OF LIGHT-ACTIVATED TISSUE REGENERATION AND THERAPY CONFERENCE, 2008, 12 : 269 - 269